ANNOUNCEMENT NO. 319
8 October 2026
The Annual General Meeting of ChemoMetec A/S was held on 8 October 2026 at 17:30 at Nordsjællands KonferenceCenter.
At the Annual General Meeting, the Board of Directors’ report on the company’s activities during the past year was presented, the annual report for 2025/26 was approved, and the Board of Directors and the Executive Board were granted discharge.
The General Meeting approved the Board of Directors’ proposal for the appropriation of profit in accordance with the annual report, including that no dividend be paid for the financial year 2025/26.
The proposal presented by the Board of Directors that the Board of Directors continues to consist of 5 members was approved. Niels Thestrup, Martin Glensbjerg, Kristine Færch, Betina Hagerup and Peter Reich were re-elected to the Board of Directors.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was elected as the company’s auditor.
The Annual General Meeting approved the remuneration report, presented by the Board of Directors.
The proposal presented by the Board of Directors to authorise the Board of Directors to acquire the company’s own shares on behalf of the company was approved.
There were no other items for consideration, after which the general meeting was adjourned.
After the general meeting, a statutory board meeting was held, where Niels Thestrup was re-elected as chairman and Martin Glensbjerg as deputy chairman.
Additional Information
Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80
Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
Attachment
